SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Paramount Skydance Corp. is a next-generation global media and entertainment company that engages in providing content creation and distribution services. It operates through the following business segments: Studios, Direct-to-Consumer, and TV Media. Its portfolio unites brands including Paramount Pictures, Paramount Television, CBS, CBS News, Nickelodeon, MTV, BET, Comedy Central, Showtime, Paramount Plus, Pluto TV, and Skydance’s Animation, Film, Television, Interactive/Games, and Sports divisions. The company was founded on June 3, 2024 and is headquartered in New York, NY.

Paramount Skydance Corp. - Ordinary Shares - Class B

Paramount Skydance (PSKY) is trending amidst its intensified pursuit of Warner Bros. Discovery (WBD), marked by a lawsuit demanding financial disclosures and plans to nominate WBD board members, positioning its all-cash offer against Netflix's bid. Concurrently, the community is buzzing with excitement over the successful debut of UFC streaming on Paramount+, anticipating significant subscriber growth and a strengthened market presence. This reflects a multi-faceted strategy to reshape its industry standing, with investors closely watching the outcome of both its M&A efforts and content initiatives.

Cadrenal Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in developing novel therapy. It develops tecarfarin, a novel therapy with orphan drug indication, designed for the prevention of systemic thromboembolism of cardiac origin in patients with end-stage renal disease and atrial fibrillation. The company was founded by Quang X. Pham and Matthew K. Szot on January 25, 2022 and is headquartered in Ponte Vedra, FL.

Cadrenal Therapeutics Inc

Cadrenal Therapeutics, Inc.

Cadrenal Therapeutics is actively discussed after recent pipeline expansion, including the acquisition of VLX-1005 for heparin-induced thrombocytopenia, complementing ongoing preparations for its lead candidate tecarfarin's Phase 3 trial. While some investors are optimistic about its FDA designations and market potential for novel anticoagulants, community sentiment is highly polarized amid concerns over frequent dilution, cash burn, and allegations of bot-driven promotion.

Avantis is the largest RWA perps DEX in DeFi, built on and backed by Base. Avantis allows users to trade crypto and real-world assets (RWAs), including FX, commodities, indices, and equities. Backed by Pantera and Coinbase, Avantis is the largest DEX on Base by volumes, and brings institutional-grade products to DeFi, letting users trade with up to 500x leverage in a transparent, permissionless environment.  Avantis is best known for launching zero-fee perpetuals (ZFP) — a first-of-its-kind primitive where traders only pay fees if they profit. They've also brought leveraged RWAs onchain. This has driven explosive growth: over $20B+ in cumulative volume and 15M+ run-rate revenues since Febrruary 2024.

Avantis

AVNT is trending as the community highlights its position as the top perpetual decentralized exchange on Coinbase's Base app, offering high leverage on various assets. While many anticipate significant price appreciation due to its low market capitalization compared to rivals, others express concern over past volatility and perceive it as a pump-and-dump.

GhostwareOS (GHOST) is the Full-Stack Privacy Layer of Solana — a next-generation AI-driven infrastructure for encrypted communication, anonymous identity management, and untraceable transactions. By combining advanced zero-knowledge protocols with autonomous AI routing, GhostwareOS allows users and developers to operate invisibly across Web3. It powers decentralized apps that demand true digital anonymity, scalable privacy, and zero metadata leakage — restoring control to users in an overexposed internet age.

Ghost

GHOST CRYPTO is gaining traction fueled by community anticipation for a potential Centralized Exchange listing and the expected launch of its GhostPay utility, which many believe will be a significant catalyst. Investors are actively discussing its 'squeezing' potential and comparing it to other fast-growing altcoins, expressing strong conviction in its future growth within the broader crypto market.

Coinbase Global, Inc. engages in the provision of a trusted platform that serves as a compliant on-ramp to the onchain economy and enables users to engage in a wide variety of activities with their crypto assets in both proprietary and third-party product experiences enabled by access to decentralized applications. It offers consumers primary financial account for the cryptoeconomy, institutions a full-service prime brokerage platform with access to deep pools of liquidity across the crypto marketplace, and developers a suite of products granting access to build onchain. The company was founded by Brian Armstrong and Fred Ernest Ehrsam in May 2012 and is headquartered in New York, NY.

Coinbase Global Inc - Ordinary Shares - Class A

Coinbase Global Inc

Coinbase is trending due to regulatory uncertainty after its CEO reportedly withdrew support for a crucial crypto bill, causing a legislative delay and prompting White House concern. The community is divided, with many noting bearish technicals and potential further downside, while others see current price levels as a strong buying opportunity for long-term growth. The ongoing debate about crypto market structure and stablecoin yield provisions continues to drive significant conversation around the platform's future.

Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980, and is headquartered in Cambridge, MA.

Sarepta Therapeutics Inc

Sarepta Therapeutics is a focal point of market discussion, driven by the imminent release of 3-year durability data for its ELEVIDYS gene therapy from the EMBARK study. The community is sharply divided, with many anticipating strong positive data to ignite a significant short squeeze and re-rate the stock, citing its current valuation and high short interest. Others are more cautious, weighing the potential for a 'sell the news' reaction against the critical nature of this long-term efficacy data for the rare disease specialist.

Q/C Technologies, Inc. operates as a clinical-stage pharmaceutical company, which engages in the development of drug products to extend healthy lifespan. It focuses on developing two novel therapeutic platforms, MyMD-1 and SUPERA-CBD, which aim to treat the causes of disease rather than just addressing the symptoms. MyMD-1 is a clinical-stage small molecule that regulates the immune system to control TNF-a, which drives chronic inflammation, and other pro-inflammatory cytokines. SUPERA-CBD is a synthetic derivative of cannabidiol being developed to treat conditions such as epilepsy, chronic pain, depression, as well as neuroinflammatory and neurodegenerative diseases. The company was founded in 1989 and is headquartered in New York, NY.

Q/C Technologies Inc.

Q/C Technologies is trending as it strengthens its pivot into photonic computing for AI, driven by the recent appointment of an OpenAI expert to its board and the bullish advocacy of advisor Martin Shkreli. Community discussion is polarized, with many anticipating a significant short squeeze due to a low float and innovative technology, while others caution against dilution risks and a potential "pump and dump" given the company's history.

Uniting the six native Japanese dog breeds. Kendu is the keeper of peace, the preserver of life, and the protector of unity. Join the pack!!

Kendu

KENDU CRYPTO is trending due to its highly active and passionate community consistently building a "permissionless brand" with real-world products like Kendu Spice and Kendu Energy drinks. The community, often rallying with "Kendu Trendu," emphasizes their commitment to long-term value creation through various IRL initiatives, distinguishing themselves from projects reliant solely on hype. This dedication to tangible development across multiple blockchain platforms (ETH, SOL, BASE) is a core talking point among supporters.

USA Rare Earth, Inc. is domestic supplier of rare earth magnets and heavy rare earth elements. It is developing a vertically integrated, domestic supply chain for rare earth element magnet production, with a facility in Stillwater, Oklahoma, and mining rights to the Round Top heavy rare earth and critical minerals deposit in West Texas. The company was founded in May 2019 and is headquartered in Stillwater, OK.

USA Rare Earth Inc. - Ordinary Shares - Class A

USA Rare Earth Inc

USA Rare Earth (USAR) is experiencing a surge in conversation following significant government investment and strategic international partnerships, fueling community optimism for a potential short squeeze and substantial price appreciation. Investors are highlighting the company's crucial role in establishing domestic rare earth supply chains, drawing comparisons to past sector beneficiaries of national security-driven funding.

HeyElsa is an AI-powered on-chain execution platform designed to simplify how users and applications interact with crypto and decentralized finance. The platform converts user intent, expressed through natural language or structured inputs, into deterministic on-chain actions such as swaps, bridging, staking, yield optimization, and automated portfolio execution across multiple blockchain networks and protocols.  HeyElsa operates through both a consumer-facing AI Copilot and a business-to-business infrastructure offering, including widgets, SDKs, and agent execution APIs that can be embedded into wallets and applications. The core purpose of the project is to abstract fragmented DeFi interfaces and execution complexity, while maintaining transparency, security, and user control. HeyElsa focuses on real usage, automation, and reliable execution rather than speculative features, aiming to make crypto transactions seamless and operationally efficient.

Elsa

ELSA is trending due to its recent listing on Coinbase, sparking significant community interest and an increase in trading activity. Investors are actively discussing its utility in AI and Zero-Knowledge Proofs on the Solana network, though some note potential profit-taking from early stakers. The asset is capturing attention amidst a broader cryptocurrency market rebound, highlighting its potential within trending tech sectors.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Modivcare caught a wave of attention from retail traders on Wednesday after it filed for Chapter 11 bankruptcy, marking a restructuring move that gives the keys to its lenders and leaves shareholders staring at the possibility of losing almost everything.&nbsp;In overnight trading, Modivcare stock fell 8.6% on top of the 12.3% drop in Wednesday’s regular session.The Denver-based healthcare group said the plan already has strong support, with more than 90% of its top lenders and over 70% of its second-tier lenders on board.&nbsp;The plan includes $100 million in fresh financing to fund operations during the bankruptcy process, giving Modivcare over $100 million in liquidity once the loan closes.The restructuring is designed to eliminate about $1.1 billion in funded debt, which accounts for over 85% of the total, and reduce interest costs, while transferring ownership of the reorganized business to its creditors.&nbsp;Modivcare said it expects to exit bankruptcy early in the fourth quarter of 2025.The bankruptcy filing follows the weakening of fundamentals. In July, the company posted a&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/modivcare-q1-earnings-miss-stock-drops-retail-sentiment-turns-bearish/chiWhC2RbkU">deeper-than-expected adjusted first-quarter loss</a> of $1.71 per share versus expectations for a $0.45 loss.&nbsp;Revenue of $650.7 million beat forecasts but fell 4.9% year-over-year due to contract attrition in its Non-Emergency Medical Transportation segment and weaker volumes in Personal Care Services and Monitoring.&nbsp;Net loss for the quarter was $50.4 million, while free cash flow was negative $86.2 million.CEO Heath Sampson said the recapitalization will strengthen the balance sheet and allow for more investment in technology and member engagement. The company has also outlined cost actions it expects will deliver more than $20 million in annualized savings.Operations across Modivcare’s transportation, personal care, and monitoring divisions are expected to continue without disruption. The company said clients, employees, and vendors will see no impact during the process.On Stocktwits, retail sentiment for ModivCare was ‘extremely bullish’ amid ‘high’ message volume.Retail users on the platform expressed worries concerning the Chapter 11 filing. A user hoped that fellow retailers got out of the stock, warning that they would get wiped out.<stembedurl>https://stocktwits.com/Mysteryman123/message/626025248</stembedurl><a href="https://stocktwits.com/symbol/MODV">ModivCare’s stock</a> has declined 84.4% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the ModivCare (Modiv Care) logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

Modivcare Files For Bankruptcy As Restructuring Hands Control To Lenders; Retail Is Wary 

The restructuring plan will cut more than $1 billion in debt and provide $100 million in fresh financing to keep operations running, although existing shareholders face the risk of being largely wiped out.

Equity

Auna S.A. (AUNA) Beats Q2 Earnings Estimates

Auna S.A. (AUNA) delivered earnings and revenue surprises of +153.85% and -3.00%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Profound Medical (PROF) Reports Q2 Loss, Misses Revenue Estimates

Profound Medical (PROF) delivered earnings and revenue surprises of -20.93% and -25.05%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

ModivCare Inc. drew bearish reactions from retail traders Thursday after the healthcare services provider reported a steeper-than-expected adjusted first-quarter loss of $1.71 per share, compared with consensus estimates for a $0.45 loss.&nbsp;The stock slipped 10.4% to $1.21 in after-hours trade despite revenue coming in ahead of expectations, after closing flat at $1.35 during regular hours.Revenue for the quarter ended March 31 was $650.7 million, above the Street’s $644.87 million forecast, but still down 4.9% from a year ago.&nbsp;The decline was attributed to contract attrition in the company’s core Non-Emergency Medical Transportation (NEMT) segment and lower volumes in its Personal Care Services (PCS) and Monitoring divisions.ModivCare posted a net loss of $50.4 million, with adjusted EBITDA of $32.6 million, flat versus the year-ago period.&nbsp;Free cash flow was negative $86.2 million, reflecting pressure from working capital build-up and higher interest expenses.&nbsp;The company remained fully drawn on its revolving credit facility, ending the quarter with $116 million in cash.CEO L. Heath Sampson said the company remains focused on key operational initiatives, including automation, cost discipline, and progress toward asset divestitures.&nbsp;Net contract receivables rose to $108.5 million from $95.2 million last quarter, driven by higher utilization on shared risk contracts.&nbsp;Management said it expects targeted cost reduction actions to generate more than $20 million in annualized savings.On Stocktwits, sentiment turned ‘bearish’ amid an 800% surge in 24-hour message volume.&nbsp;One user warned that ModivCare may not survive, noting analysts on the earnings call pressed management on how it would meet two large interest payments this year — without receiving a clear answer.&nbsp;The user speculated that bondholders could take control, calling the stock “a lotto ticket.”&nbsp;<stembedurl>https://stocktwits.com/pilobious/message/614015091</stembedurl>Another user braced for sharp losses, saying a “bloodbath” was likely in the next session.<stembedurl>https://stocktwits.com/slick3333/message/614014310</stembedurl>The stock has declined 89% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

ModivCare Stock Tumbles After-Hours As Q1 Loss Widens: Retail Traders Warn Of 'Bloodbath'

The healthcare company reported a steeper-than-expected adjusted Q1 loss of $1.71 per share, compared to the consensus estimate of a $0.45 loss. 

ModivCare, Inc. is a technology-enabled healthcare services company, which engages in the provision of a suite of integrated supportive care solutions for public and private payors and their members. It operates through the following segments: Non-Emergency Medical Transportation (NEMT), Personal Care, Remote Patient Monitoring (RPM), and Corporate and Other. The NEMT segment is involved in the non-emergency medical transportation programs for state governments and managed care organizations, or MCOs, in the U.S. The Personal Care segment offers home personal care services to State and Managed Medicaid, Medicare, and Private Pay patient populations in need of care monitoring and assistance performing activities of daily living. The RPM segment focuses on remote patient monitoring solutions, including personal emergency response systems, vitals monitoring, and data-driven patient engagement solutions. The Corporate and Other segment includes the costs associated with the company's corporate operations. The company was founded by Fletcher Jay McCusker in December 1996 and is headquartered in Denver, CO.

ModivCare Inc

$MSFT

$AAPL

$TSLA

$META

Earnings season is heating up, and several major companies report next week, including Microsoft, Apple, Tesla, and Meta. Which are you most excited for?

Which earnings report are you most excited for next week? 
 
Drop a comment for others.

MODV
ModivCare Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest MODV News

MODVModivCare Inc